Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Abingdon Health announced it will commence trading on the U.S. OTCQB market in April, extending its existing listing on the AIM exchange. The move follows the opening of a manufacturing facility in Madison, Wisconsin, a state known for its health‑tech ecosystem, and aims to tap a growing local investor base. Company executives highlighted that the OTCQB platform enables U.S. investors to buy shares in dollars during U.S. market hours, while the underlying securities continue to be issued on AIM. This dual‑listing structure is expected to improve share liquidity and streamline access for American shareholders. Chris, the spokesperson, emphasized that “trading on the OTC platform should benefit the liquidity of our shares and the shareholder base as a whole,” noting that trades will flow through to AIM but be executed domestically. The listing could broaden Abingdon’s investor pool, raise its profile in the U.S. health‑technology sector, and potentially lower capital‑raising costs, positioning the company for accelerated growth and profitability.
Question: If a transcript has a CDS that starts with two methionines, what's the general rule for sequence annotation? Should I make it so if two METs in a row at the beginning, annotate the closest MET to rest of sequence...
Woah. I'm slightly embarrassed that I missed this for a few weeks. Finally there is approval, in a Large Nation, for a stem cell-based REPLACEMENT therapy for an age-related condition. The condition is, no surprise, Parkinson's, which I always highlight...
Life Sciences Today host Danny Lieberman interviews Zena Sarif, founder of Yandu, about the chronic inefficiencies that prolong clinical‑trial timelines and how her startup aims to streamline the process. Sarif explains that up to 12‑18 months of a drug’s development are...
ARS Pharmaceuticals (ticker SPRY) received FDA approval to broaden the label of its Neffy 1 mg needle‑free epinephrine nasal spray, eliminating the previous age restriction and allowing use by anyone weighing at least 33 lb. The change expands market access for the...
Researchers at the University of Colorado Boulder have identified a python‑derived metabolite, para‑tyramine‑O‑sulfate (pTOS), that spikes dramatically after the snakes eat and appears to suppress appetite. In mouse studies, high doses of pTOS triggered weight loss without the gastrointestinal side...
The U.S. Centers for Disease Control and Prevention has temporarily stopped rabies and pox virus testing because severe staffing shortages have left the rabies unit with a single specialist and the pox unit without any experts. The pause affects more...
Zeto has secured FDA 510(k) clearance for its New Wave outpatient EEG system, enabling use in clinics and homes. The device features 21 soft‑tip electrodes covering the full 10–20 system and integrates synchronized video and audio capture. It supports recordings...
Recent comparative studies indicate tirzepatide outperforms semaglutide in accelerating fat loss. Tirzepatide’s dual activation of GLP‑1 and GIP receptors delivers stronger appetite suppression, improved insulin sensitivity, and enhanced lipid metabolism, leading to higher average weight‑loss percentages. Semaglutide remains effective by...
Merck has launched the pivotal Phase IIb/III MALBEC trial to evaluate MK‑8748 (Tiespectus/EYE201) in patients with neovascular age‑related macular degeneration (NVAMD). The study pits two intravitreal dose levels of the bispecific TIE2‑agonist/VEGF‑inhibitor against aflibercept 2 mg, beginning with quarterly injections for three...
Dynamics of blood NAD and glutathione in health, disease, aging and under NAD-booster treatment “In healthy population (n=299;18-70 year-olds) redox metabolites follow normal distribution in blood and remain unchanged during aging. NAD-boosting increased 4-6 fold the blood NAD+ depending on individual,...
Earendil Labs has dosed the first patient in a Phase IIa, randomized, placebo‑controlled trial of its half‑life‑extended anti‑TL1A antibody HXN‑1001 for ulcerative colitis. The company also completed enrollment for the Phase I study in healthy volunteers in Australia, where single doses up...
Epia Neuro, a San Francisco‑based startup, announced a brain‑computer interface implant paired with a motorized glove designed to restore hand function in stroke survivors. The device aims to rewire neural pathways and address the two‑thirds of patients who experience lasting...
SpectraCell Laboratories introduced Baseline Nexus, a single‑kit bundle that merges micronutrient profiling, lipoprotein particle analysis, telomere length measurement, and MTHFR genotyping. The Houston‑based firm says the package lets biohackers spot hidden health risks before symptoms appear, aiming to shift preventive...
A new systematic review in BMC Geriatrics finds that levothyroxine offers no measurable benefit for older adults with subclinical hypothyroidism. Patient‑reported quality‑of‑life, cognitive function, physical performance, and major cardiovascular events were unchanged compared with observation or placebo. The analysis also...
BillionToOne, Inc. saw its Nasdaq‑listed shares drop 3.66% to $79.92 following the announcement that Allen Chen will lead medical affairs and clinical development for oncology. The move comes as the company expands its Northstar liquid‑biopsy platform, and investors are weighing...
New study has strengthened link between infectious mono and Multiple Sclerosis. By analyzing 2 decades of health records, researchers found people who contracted mono as teenagers or adults were 3x more likely to develop MS later vs those who didn’t https://t.co/6DLZMEWyU6
